First blood-based biomarker in response to the treatment of the most aggressive prostate cancer
The most aggressive type of prostate cancer, castration-resistant prostate cancer, can be treated via two therapies: taxanes or hormone treatment. Until recently, there were no comparative studies between the two, and the ...